Thrombophilia and thrombosis in systemic lupus erythematosus: A case-control study [1]

Annals of the Rheumatic Diseases

Volumn 62, Issue 10, 2003, Pages 1016-1017

  Barcat, D ^a   Guerin V ^b   Ryman, A ^b   Constans, J ^a   Vernhes, J P ^c   Vergnes, C ^d   Bonnet, F ^a   Delbrel, X ^a   Morlat, P ^a   Longy Boursier, M ^a   Conri, C ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

^c Robert Boulin Hospital   (France)

^d Hop du Haut Leveque ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; METHIONINE; PHOSPHOLIPID ANTIBODY; PROTEIN S; PROTHROMBIN ANTIBODY; THROMBOPLASTIN; VITAMIN K GROUP;

ACTIVATED PROTEIN C RESISTANCE; ALLELE; ARTERY THROMBOSIS; BONE NECROSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE MUTATION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; LETTER; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOPHILIA; THROMBOPLASTIN TIME; THROMBOSIS;

ANTIBODIES, ANTICARDIOLIPIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROTEIN S; THROMBOPHILIA; THROMBOSIS;

EID: 0141762489     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.10.1016     Document Type: Letter

References (9)

1. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLEq disorders. Ann Intern Med 1990;112:682-98.
2. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemost 1996;76:916-24.
3. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk of venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. Lupus 1997;6:467-73.
4. Tornas JF, Alberca I, Tabernero MD, Cordero M, Del Pino-Montes J, Vicente V. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1998;25:57-62.
5. Sorice M, Griggi T, Circella, Lenti L, Arcieri P, Domenico di Nucci G, et al. Protein S antibodies in acquired protein S deficiencies. Blood 1994;83:2383-4.
6. Kiraz S, Ertenli I. Benekli M, Haznedaroglu IC, Calguneri M, Celik I, et al. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999;8:737-41.
7. Ferro D, Quintarelli C, Valesini G, Violi F. Lupus anticoagulant and increased thrombin generation inpatients with systemic lupus erythematosus. Blood 1994;83:304-5.
8. Patri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in lupus erythematosus. Lancet 1996;348:1120-4.
9. Fijnheer R, Roast M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998;25:1737-42.